ArticlePeerJ2020
Insights on early mutational events in SARS-CoV-2 virus reveal founder effects across geographical regions.
Article in PeerJ, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 44 citations in OpenAlex.
- A Critical Reexamination of Recovered SARS-CoV-2 Sequencing Data.Molecular biology and evolution · 2025Article
- The Data are Insufficient to Confidently Root the SARS-CoV-2 Phylogenetic Tree.Molecular biology and evolution · 2025Article
- JN.1 variants circulating in Italy from October 2023 to April 2024: genetic diversity and immune recognition.BMC infectious diseases · 2025Article
- Tracking SARS-CoV-2 variants in wastewater in San Pedro de la Paz, Chile.Journal of water and health · 2024Article
- Advances and Challenges in SARS-CoV-2 Detection: A Review of Molecular and Serological Technologies.Diagnostics (Basel, Switzerland) · 2024Review
- Persistence of a Frameshifting Deletion in SARS-CoV-2 ORF7a for the Duration of a Major Outbreak.Viruses · 2023Article
- Genomic surveillance of SARS-CoV-2 in Weihai, China, march 2022 to march 2023.Frontiers in public health · 2023Article
- Isothermal amplification-assisted diagnostics for COVID-19.Biosensors & bioelectronics · 2022Review
- The first three waves of the Covid-19 pandemic hint at a limited genetic repertoire for SARS-CoV-2.FEMS microbiology reviews · 2022Article
- Diagnostic assay and technology advancement for detecting SARS-CoV-2 infections causing the COVID-19 pandemic.Analytical and bioanalytical chemistry · 2022Review
- Advancements in detection of SARS-CoV-2 infection for confronting COVID-19 pandemics.Laboratory investigation; a journal of technical methods and pathology · 2022Review
- Recovery of Deleted Deep Sequencing Data Sheds More Light on the Early Wuhan SARS-CoV-2 Epidemic.Molecular biology and evolution · 2021Article
- CoVrimer: A tool for aligning SARS-CoV-2 primer sequences and selection of conserved/degenerate primers.Genomics · 2021Article
- Article
- Article
- SARS-CoV-2 genomic diversity and the implications for qRT-PCR diagnostics and transmission.Genome research · 2021Article
- Molecular Analysis of SARS-CoV-2 Genetic Lineages in Jordan: Tracking the Introduction and Spread of COVID-19 UK Variant of Concern at a Country Level.Pathogens (Basel, Switzerland) · 2021Article
- Cross-reactivity and inclusivity analysis of CRISPR-based diagnostic assays of coronavirus SARS-CoV-2.PeerJ · 2021Article
- Temporal increase in D614G mutation of SARS-CoV-2 in the Middle East and North Africa.Heliyon · 2021Article
- Introduction and Characteristics of SARS-CoV-2 in North-East of Romania During the First COVID-19 Outbreak.Frontiers in microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Here we aim to describe early mutational events across samples from publicly available SARS-CoV-2 sequences from the sequence read archive and GenBank repositories. Up until 27 March 2020, we downloaded 50 illumina datasets, mostly from China, USA (WA State) and Australia (VIC). A total of 30 datasets (60%) contain at least a single founder mutation and most of the variants are missense (over 63%). Five-point mutations with clonal (founder) effect were found in USA next-generation sequencing samples. Sequencing samples from North America in GenBank (22 April 2020) present this signature with up to 39% allele frequencies among samples (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.